Investors Join Class Action Against Skye Bioscience Over Allegations of Misleading Claims

Investor Alert: Class Action Against Skye Bioscience, Inc.

Recently, Robbins LLP announced a class action lawsuit against Skye Bioscience, Inc. (NYSE: FCX) aimed at protecting investors who acquired securities from November 4, 2024, to October 3, 2025. This biopharmaceutical company, known for its focus on developing treatments for obesity and metabolic diseases, has faced scrutiny regarding the efficacy of its lead drug candidate, nimacimab.

Allegations of Misrepresentation

The class action has arisen from claims that Skye Bioscience misled investors about the viability and effectiveness of nimacimab. According to court documents, it has been alleged that the company did not adequately disclose critical information during the class period which would have significantly influenced investor decisions. Specifically, claims indicate that nimacimab’s effectiveness was overstated, which has now raised questions about the drug’s clinical, regulatory, and market potential.

The crux of the complaint rests on a press release issued by Skye on October 6, 2025, which shared disappointing results from the Phase 2a CBeyond™ study of nimacimab. The study aimed to demonstrate significant weight loss in participants using the drug compared to a placebo. Unfortunately, it revealed that nimacimab did not meet its primary endpoint, causing the stock to tumble by $2.85, or a staggering 60%, by the close of that trading day.

Implications for Investors

This significant drop in stock price has led many investors to feel misled and seek redress. Under such class actions, shareholders have the opportunity to unite and address grievances against potential corporate malfeasance. Those who believe they have been affected by these developments need to take steps to potentially lead the case as a representative party, known as the lead plaintiff, which plays a crucial role in guiding the litigation process.

Robin LLP is actively encouraging affected shareholders to contact them for information on how to participate or get involved. Importantly, shareholders might opt to remain passive without loss of their rights to recovery during the proceedings.

About Robbins LLP

Robbins LLP has established itself as a leader in shareholder rights litigation, committed to helping investors recover losses while pushing for accountability within corporations. Since its inception in 2002, the firm’s attorneys have dedicated their expertise to ensuring enhanced corporate governance and addressing wrongdoings by company executives.

Moreover, investors can subscribe to Stock Watch to receive timely updates regarding any potential settlements in cases involving Skye Bioscience or alerts concerning changes in corporate conduct that may impact their investments.

As the legal landscape continues to evolve, the outcome of this case may serve as a pivotal moment for both Skye Bioscience and its investors. Shareholders are urged to stay informed and take appropriate action to protect their investments as this class action unfolds.